Premier Alternatives

Rgenta Therapeutics

Woburn, MA · Founded 2018 · Privately Held (backing)

Developer of a data-driven mRNA target identification platform intended to develop RNA-targeting medicines. Rgenta Therapeutics is based in Woburn, MA and was founded in 2018. It was valued at $119 million at its later-stage round in Nov 2022, the last priced event on record. It has raised $98.9 million across 2 recorded rounds; the latest was an $8.9 million early-stage round in Nov 2021.

PMV mark · valuation
$119.0M
Oct 2026
Priced at
its later-stage round
Nov 2022
Total raised
$98.9M
Last round
Early Stage VC
Nov 2021

Rgenta Therapeutics key facts

as of Oct 2026
  • Developer of a data-driven mRNA target identification platform intended to develop RNA-targeting medicines.
  • Rgenta Therapeutics is valued at approximately $119.0M as of Oct 2026, set at its later-stage round, Nov 2022; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $98.9M across 2 recorded rounds; the latest was Early Stage VC ($8.9M) in Nov 2021.
  • Notable investors include Korea Investment Partners, CICC Capital, Legend Star, EQT Ventures, Vivo Capital — 13 tracked in total.
  • Rgenta Therapeutics has filed 3 Form Ds with the SEC since 2020, most recently Feb 2022 ($8.9M sold to 6 investors).
  • Status: Privately Held (backing).
PrivateMarketView mark
LOW confidence
$119.0M

Valued at $119.0M at its later-stage round, Nov 2022. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of Rgenta Therapeutics with a free account
  • ·The complete investor list: 13 names
  • ·Watch Rgenta Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Rgenta Therapeutics funding rounds

2 rounds
Nov 2021Early Stage VC$8.9MSEC filing▮
Jan 2020Early Stage VC$10.0MSEC filing▮
Full funding history →

Rgenta Therapeutics valuation

Rgenta Therapeutics was valued at $119 million at its later-stage round in Nov 2022. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Rgenta Therapeutics raised?

Rgenta Therapeutics has raised $98.9 million in total; 2 of its rounds are on record. The largest on record was an $8.9 million early-stage round in Nov 2021.

Rgenta Therapeutics has filed 3 Form Ds with the SEC since 2020, most recently in Feb 2022 ($8.9 million sold to 6 investors).

Rgenta Therapeutics investors

13 investors are on record for Rgenta Therapeutics, including Korea Investment Partners, CICC Capital, Legend Star and EQT Ventures. By type, the record holds 4 venture capital firms and 1 private equity firm. The early-stage round in Nov 2021 drew 6 investors.

About Rgenta Therapeutics

Developer of a data-driven mRNA target identification platform intended to develop RNA-targeting medicines. The company's platform offers a custom-designed compound library incorporating the physicochemical properties of RNA-binding moieties that account for cell type-specific target regulation and predict the biological consequences of target modulation, enabling medical practitioners to target messenger RNAs of disease genes and open up opportunities for drug development.

Sector
Healthcare
HQ
Woburn, MA, United States
Founded
2018
Employees
30
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.